Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 179

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 179
---
 identify promising          
 tumor antibodies, antibody conjugates, and antigens. We focus on tumor targets of product candidates previously tested in clinical trials by other biopharmaceutical companies and where the trials results were made available, the rationale for 
 discontinuation of such product candidates were well-known and where we have identified opportunities for differentiation. We also prioritize those targets that we believe have both strong precedent data and potential broader applicability,   
 including expansion beyond the indications in which they were initially tested.                                                                                                                                                                    |

| • |     | We innovate antibody design to improve ADC performance. We strive to develop ADCs that couple next                                                                                                            
 wave ADC architecture with cutting-edge antibody strategies to further improve antibody performance, including, but not limited to, high affinity, biparatopic/bi-specific, epitope and Fc modifications that 
 increase ADC potency or safety.                                                                                                                                                                               |

| • |     | We focus our development strategies to demonstrate differentiation of our assets compared to first                                                                                                                                                                                                                                                                                                                                    
 generation ADCs to maximize our asset’s competitive profile. Our development strategy leverages precedent data from first generation ADCs to benchmark potential improvements to guide further expansion in both precedent and non-precedent indications. We also plan to pursue combination strategies early in our programs to reach more patients and take full advantage of Project Frontrunner, the FDA’s effort to shift cancer 
 therapeutics development in earlier lines of therapy.                                                                                                                                                                                                                                                                                                                                                                                 |

| • |     | We utilize an efficient virtual model with outsourced clinical development and manufacturing. We                                                                                                                                                                                                                                                                                
 plan to utilize an outsourced model for research, development and manufacturing operations. Initially, we intend to continue to benefit from the continuity of partnership with WuXi Biologics and Hangzhou DAC for near-term IND-enabling studies and ADC manufacturing. We will expand our CRDMO network as appropriate as our portfolio advances further in clinical trials. |

| • |     | We look to continue to build our portfolio through strategic partnerships. We plan to continue to                                                                        
 use our management and board expertise, as well as our extensive network, to maximize and grow our portfolio through additional strategic partnerships and transactions. |

Our Portfolio We were deliberate in identifying promising tumor targets that are broadly expressed across multiple cancer types, and plan to focus our initial development efforts on high potential indications where first generation ADCs against these targets have already shown proof of concept in Phase 1 clinical trials. The three tumor targets we selected – PTK7, MUC16 and SEZ6 – are each validated by a first generation ADC that demonstrated promising efficacy